United Services Automobile Association reduced its position in shares of AtriCure, Inc. (NASDAQ:ATRC) by 3.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 80,365 shares of the medical device company’s stock after selling 3,205 shares during the period. United Services Automobile Association’s holdings in AtriCure were worth $1,539,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently made changes to their positions in ATRC. Rockefeller Financial Services Inc. increased its stake in shares of AtriCure by 185.0% in the first quarter. Rockefeller Financial Services Inc. now owns 11,766 shares of the medical device company’s stock valued at $225,000 after buying an additional 7,637 shares during the last quarter. Essex Investment Management Co. LLC boosted its stake in shares of AtriCure by 9.4% in the first quarter. Essex Investment Management Co. LLC now owns 119,189 shares of the medical device company’s stock valued at $2,282,000 after buying an additional 10,261 shares during the period. Perkins Capital Management Inc. boosted its stake in shares of AtriCure by 7.4% in the first quarter. Perkins Capital Management Inc. now owns 137,217 shares of the medical device company’s stock valued at $2,628,000 after buying an additional 9,467 shares during the period. Skylands Capital LLC boosted its stake in shares of AtriCure by 269.2% in the first quarter. Skylands Capital LLC now owns 53,350 shares of the medical device company’s stock valued at $1,022,000 after buying an additional 38,900 shares during the period. Finally, Bank of Montreal Can boosted its stake in shares of AtriCure by 1.2% in the first quarter. Bank of Montreal Can now owns 10,462 shares of the medical device company’s stock valued at $200,000 after buying an additional 128 shares during the period. 86.46% of the stock is owned by institutional investors.
AtriCure, Inc. (NASDAQ ATRC) traded down 0.54% on Friday, reaching $23.74. 230,837 shares of the company’s stock traded hands. The firm’s 50 day moving average price is $23.14 and its 200 day moving average price is $19.87. AtriCure, Inc. has a 12 month low of $13.45 and a 12 month high of $25.11. The company’s market cap is $805.88 million.
AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, May 4th. The medical device company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. AtriCure had a negative return on equity of 19.89% and a negative net margin of 21.07%. The company had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $40.25 million. During the same period last year, the business posted ($0.31) earnings per share. The firm’s revenue was up 15.0% compared to the same quarter last year. On average, equities analysts expect that AtriCure, Inc. will post ($0.96) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.baseball-news-blog.com/2017/07/22/atricure-inc-atrc-position-cut-by-united-services-automobile-association-updated-updated.html.
Several equities analysts have recently commented on ATRC shares. Zacks Investment Research upgraded shares of AtriCure from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research report on Tuesday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $25.00 price target (up from $23.00) on shares of AtriCure in a report on Friday, May 5th. Canaccord Genuity reaffirmed a “buy” rating and set a $22.00 price target on shares of AtriCure in a report on Monday, April 17th. TheStreet raised shares of AtriCure from a “d+” rating to a “c-” rating in a report on Monday, May 15th. Finally, ValuEngine raised shares of AtriCure from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $22.60.
In related news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total transaction of $214,400.00. Following the completion of the transaction, the director now directly owns 24,162 shares in the company, valued at $518,033.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.00% of the company’s stock.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.